Drug intelligence / Profile preview

Myncov1006

Development stage: Preclinical
Lead developer: Mynvax
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Myncov1006 is an engineered, recombinant protein subunit vaccine candidate developed by Mynvax for the prevention of COVID-19. The vaccine is designed to target the Receptor Binding Domain (RBD) and other highly conserved regions of the SARS-CoV-2 Spike protein to elicit a broad and potent immune response. A key feature of Mynvax's technology is the development of thermostable 'warm vaccines' that can withstand higher temperatures, potentially simplifying distribution by reducing reliance on cold-chain infrastructure. Myncov1006 is intended to provide protection against multiple variants of the virus by focusing on epitopes that are less prone to mutation. It is currently in the preclinical stage of development.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on Myncov1006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myncov1006.

Explore the full profile